Spyre Therapeutics (SYRE) Non-Current Deferred Tax Liability (2015 - 2017)
Spyre Therapeutics' (SYRE) quarterly Non-Current Deferred Tax Liability came in at $63000.0 in Q4 2017, up 5.0% YoY from $60000.0 in Q4 2016, and up 5.0% on a QoQ basis from $60000.0 in Q4 2016.
Spyre Therapeutics (SYRE) Non-Current Deferred Tax Liability (2015 - 2017) Analysis & Trends
Spyre Therapeutics (SYRE) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $63000.0 in Q4 2017.
- Quarterly Non-Current Deferred Tax Liability rose 5.0% year-over-year to $63000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $63000.0 (up 5.0% YoY) and the FY2017 annual result came in at $63000.0, up 5.0% from the prior year.
- Non-Current Deferred Tax Liability climbed to $63000.0 in Q4 2017, from $60000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $63000.0 in Q4 2017 to a low of $49000.0 in Q4 2015.
- A 3-year average of $57333.3 and a median of $60000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2016 — Non-Current Deferred Tax Liability advanced 22.45% — and 2017, when it climbed 5.0%.
- Tracing SYRE's Non-Current Deferred Tax Liability over 3 years: stood at $49000.0 in 2015, then climbed by 22.45% to $60000.0 in 2016, then gained by 5.0% to $63000.0 in 2017.
- The last three Non-Current Deferred Tax Liability figures came in at $63000.0 (Q4 2017), $60000.0 (Q4 2016), and $49000.0 (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 63,000.00 |
| Dec 31, 2017 | 63,000.00 |
| Dec 31, 2016 | 60,000.00 |
| Dec 31, 2016 | 60,000.00 |
| Dec 31, 2015 | 49,000.00 |
| Dec 31, 2015 | 49,000.00 |